{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:17:39Z","timestamp":1789168659470,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10787-024-01614-9","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:37:46Z","timestamp":1733949466000},"page":"91-104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmaceutical aspects of JAK inhibitors: a comparative review"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-0744","authenticated-orcid":false,"given":"Sandhya","family":"Jinesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"1614_CR1","unstructured":"Ahmad A, Zaheer M, Balis FJ (2024). Baricitinib. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34283430"},{"key":"1614_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104157","volume":"80","author":"E Ali","year":"2022","unstructured":"Ali E, Owais R, Sheikh A, Shaikh A (2022) Olumniant (Baricitinib) oral tablets: an insight into FDA-approved systemic treatment for alopecia areata. Ann Med Surg (Lond) 80:104157. https:\/\/doi.org\/10.1016\/j.amsu.2022.104157","journal-title":"Ann Med Surg (Lond)"},{"key":"1614_CR3","unstructured":"Anderson, L. A. (2023). Which JAK inhibitors are approved in the U.S? https:\/\/www.drugs.com\/medical-answers\/jak-inhibitors-approved-3575793\/."},{"key":"1614_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/biom10071002","author":"J Angelini","year":"2020","unstructured":"Angelini J, Talotta R, Roncato R, Fornasier G, Barbiero G, Dal Cin L, Brancati S, Scaglione F (2020) JAK-Inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future. Biomolecules. https:\/\/doi.org\/10.3390\/biom10071002","journal-title":"Biomolecules"},{"key":"1614_CR5","unstructured":"FDA Approves JAK Inhibitor Deuruxolitinib for Alopecia Areata - Medscape. (2024). Medscape - https:\/\/www.medscape.com\/viewarticle\/fda-approves-jak-inhibitor-deuruxolitinib-alopecia-areata-2024a1000dsz?form=fpf."},{"issue":"2","key":"1614_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD (2018) Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis? Ann Rheum Dis 77(2):175\u2013187. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211555","journal-title":"Ann Rheum Dis"},{"key":"1614_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106359","volume":"183","author":"M Benucci","year":"2022","unstructured":"Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, Gobbi FL, Sarzi-Puttini P (2022) Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted. Pharmacol Res 183:106359. https:\/\/doi.org\/10.1016\/j.phrs.2022.106359","journal-title":"Pharmacol Res"},{"issue":"12","key":"1614_CR8","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"JD Clark","year":"2014","unstructured":"Clark JD, Flanagan ME, Telliez JB (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57(12):5023\u20135038. https:\/\/doi.org\/10.1021\/jm401490p","journal-title":"J Med Chem"},{"key":"1614_CR33","doi-asserted-by":"publisher","first-page":"1759720X1989929","DOI":"10.1007\/s10278-019-00219-x","volume":"12","author":"G Costanzo","year":"2020","unstructured":"Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S (2020) Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis 12:1759720X19899296. https:\/\/pubmed.ncbi.nlm.nih.gov\/32071617\/","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"1614_CR9","unstructured":"COVID-19 update: baricitinib (Olumiant) FDA-approved for treatment of COVID-19. (2022). Med Lett Drugs Ther, 64(1652), e2-e3. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35657369"},{"issue":"1","key":"1614_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10278-019-00219-x","volume":"33","author":"A Elovic","year":"2020","unstructured":"Elovic A, Pourmand A (2020) Lexicomp app review. J Digit Imaging 33(1):17\u201320. https:\/\/doi.org\/10.1007\/s10278-019-00219-x","journal-title":"J Digit Imaging"},{"key":"1614_CR11","unstructured":"Haq, M., & Adnan, G. (2024). Ruxolitinib. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34033362"},{"key":"1614_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15020385","author":"H Iznardo","year":"2023","unstructured":"Iznardo H, Roe E, Serra-Baldrich E, Puig L (2023) Efficacy and safety of JAK1 inhibitor abrocitinib in atopic dermatitis. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15020385","journal-title":"Pharmaceutics"},{"issue":"2\u20133","key":"1614_CR13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10787-015-0229-0","volume":"23","author":"S Jinesh","year":"2015","unstructured":"Jinesh S (2015) Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs. Inflammopharmacology 23(2\u20133):71\u201377","journal-title":"Inflammopharmacology"},{"issue":"11","key":"1614_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000963","volume":"7","author":"JJ Kiladjian","year":"2023","unstructured":"Kiladjian JJ, Vannucchi AM, Gerds AT, Gupta V, Verstovsek S, Egyed M, Platzbecker U, Mayer J, Grosicki S, Illes A, Wozny T, Oh ST, McLornan D, Kirgner I, Yoon SS, Harrison CN, Klencke B, Huang M, Kawashima J, Mesa R (2023) Momelotinib in myelofibrosis patients with thrombocytopenia: post hoc analysis from three randomized phase 3 trials. Hemasphere 7(11):e963. https:\/\/doi.org\/10.1097\/HS9.0000000000000963","journal-title":"Hemasphere"},{"key":"1614_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.06.097","author":"B King","year":"2024","unstructured":"King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, Prajapati VH, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman MC, Hamilton C, Cassella J (2024) Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.097","journal-title":"J Am Acad Dermatol"},{"key":"1614_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015209","author":"A Kramer","year":"2022","unstructured":"Kramer A, Prinz C, Fichtner F, Fischer AL, Thieme V, Grundeis F, Spagl M, Seeber C, Piechotta V, Metzendorf MI, Golinski M, Moerer O, Stephani C, Mikolajewska A, Kluge S, Stegemann M, Laudi S, Skoetz N (2022) Janus kinase inhibitors for the treatment of COVID-19. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD015209","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1614_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y (2023) JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 32(4):333\u2013344. https:\/\/doi.org\/10.1080\/13543784.2023.2199919","journal-title":"Expert Opin Investig Drugs"},{"key":"1614_CR32","unstructured":"LexiComp. UpToDate Lexidrug. UpToDate Inc. https:\/\/online.lexi.com. Accessed 28 Apr 2024"},{"issue":"4","key":"1614_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","volume":"148","author":"Y Luo","year":"2021","unstructured":"Luo Y, Alexander M, Gadina M, O\u2019Shea JJ, Meylan F, Schwartz DM (2021) JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol 148(4):911\u2013925. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.004","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1614_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41392-024-01934-w","volume":"9","author":"Y Lv","year":"2024","unstructured":"Lv Y, Qi J, Babon JJ, Cao L, Fan G, Lang J, Zhang J, Mi P, Kobe B, Wang F (2024) The JAK-STAT pathway: from structural biology to cytokine engineering. Signal Transduct Target Ther 9(1):221. https:\/\/doi.org\/10.1038\/s41392-024-01934-w","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"1614_CR20","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","volume":"15","author":"J Mascarenhas","year":"2022","unstructured":"Mascarenhas J (2022) Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia. Expert Rev Hematol 15(8):671\u2013684. https:\/\/doi.org\/10.1080\/17474086.2022.2112565","journal-title":"Expert Rev Hematol"},{"key":"1614_CR21","unstructured":"Padda IS, Bhatt R, Parmar M (2024). Tofacitinib. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34283514"},{"key":"1614_CR22","unstructured":"Padda IS, Bhatt R, Patel P, Parmar M (2024). Upadacitinib. In StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34283454"},{"issue":"4","key":"1614_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/17474086.2022.2112565","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, Simpson EL (2021) Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol 85(4):863\u2013872. https:\/\/pubmed.ncbi.nlm.nih.gov\/33957195\/","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1614_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/10600280221096713","volume":"57","author":"PO Perche","year":"2023","unstructured":"Perche PO, Cook MK, Feldman SR (2023) Abrocitinib: a new FDA-approved drug for moderate-to-severe atopic dermatitis. Ann Pharmacother 57(1):86\u201398. https:\/\/doi.org\/10.1177\/10600280221096713","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1614_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s43556-023-00151-1","volume":"4","author":"A Sarapultsev","year":"2023","unstructured":"Sarapultsev A, Gusev E, Komelkova M, Utepova I, Luo S, Hu D (2023) JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions. Mol Biomed 4(1):40. https:\/\/doi.org\/10.1186\/s43556-023-00151-1","journal-title":"Mol Biomed"},{"issue":"1","key":"1614_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2021","unstructured":"Talpaz M, Kiladjian JJ (2021) Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35(1):1\u201317. https:\/\/doi.org\/10.1038\/s41375-020-0954-2","journal-title":"Leukemia"},{"issue":"3","key":"1614_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133\u2013145. https:\/\/doi.org\/10.1038\/s41584-021-00726-8","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"1614_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00033-X","volume":"6","author":"R The Lancet","year":"2024","unstructured":"The Lancet R (2024) JAK inhibitors-friend or foe? Lancet Rheumatol 6(3):e129. https:\/\/doi.org\/10.1016\/S2665-9913(24)00033-X","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"1614_CR28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","volume":"19","author":"K Tokareva","year":"2023","unstructured":"Tokareva K, Reid P, Yang V, Liew D, Peterson AC, Baraff A, Giles J, Singh N (2023) JAK inhibitors and black box warnings: what is the future for JAK inhibitors? Expert Rev Clin Immunol 19(11):1385\u20131397. https:\/\/doi.org\/10.1080\/1744666X.2023.2249237","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"1614_CR29","doi-asserted-by":"publisher","first-page":"481","DOI":"10.5114\/reum\/177005","volume":"61","author":"KM Tyczynska","year":"2023","unstructured":"Tyczynska KM, Augustyniak-Bartosik H, Swierkot J (2023) Rheumatoid arthritis\u2014medication dosage in chronic kidney disease. Reumatologia 61(6):481\u2013491. https:\/\/doi.org\/10.5114\/reum\/177005","journal-title":"Reumatologia"},{"issue":"16","key":"1614_CR30","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","volume":"6","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Mascarenhas J (2022) The odyssey of pacritinib in myelofibrosis. Blood Adv 6(16):4905\u20134913. https:\/\/doi.org\/10.1182\/bloodadvances.2022007524","journal-title":"Blood Adv"},{"key":"1614_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S (2020) The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210","journal-title":"Int Immunopharmacol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01614-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01614-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:31:34Z","timestamp":1738729894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01614-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01614-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"assertion":[{"value":"29 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We do not have any conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}